tbuckley/cabot-search huggingface dataset:
Patterns of disease spread in metastatic mucosal melanoma.
Authors: K. N. O'Regan, N. H. Ramaiya, J. P. Jagannathan, P. Dipiro, A. D. Van Den Abbeele, F. S. Hodi
Journal: Journal of Clinical Oncology (2010)

8583 Background: Mucosal melanoma is a rare but aggressive subtype of melanoma whose clinicopathologic characteristics are poorly understood. Traditionally viewed as a single entity, mucosal melanoma can arise from different anatomical sites. We hypothesize that mucosal melanoma from different primary sites shows predilection for separate and unique metastatic pathways. Methods: IRB approval was obtained for this retrospective analysis of 18 patients with metastatic mucosal melanoma (11F: 7M, mean age 58 yrs, range: 38-76). Medical records, pathology, and radiologic studies were evaluated for site and characteristics of the primary tumor, initial stage, and sites of metastatic involvement. Results: Primary sites included anus (n=5), rectum (n=3), vagina (n= 6), and sinonasal cavity (n=4). Mean follow-up was 12.6 months (range 1-29). At presentation, 39% (n=7) had regional nodal metastasis and 22% (n=4) had distant metastatic disease. At follow-up, 83% (n=15) developed distant metastases (Table). Liver metastases were most common with sinonasal melanoma, while brain metastases occurred infrequently in all groups. Anal melanoma shows a predilection for regional nodal spread, with infrequent visceral metastases. Conversely, rectal melanoma commonly metastasizes to lung, liver, and peritoneum. Subcutaneous metastases were relatively rare, occurring in only 2 patients (11%). However, the sample size is too small to achieve any statistical significance. Conclusions: The primary site of mucosal melanoma is important for predicting the pattern of metastatic spread. Traditionally viewed as a single entity, the very different patterns of spread for anal and rectal melanoma suggest that each may have a unique metastatic pattern. Knowledge of these metastatic patterns may help clinicians and radiologists in the planning and interpretation of imaging studies and in the management of these patients. Primary site (n) Lung Liver Peritoneum Brain Regional nodes Sinonasal 100% (4) 100% (4) 50% (2) 0 100% (4) Vaginal 67% (4) 67% (4) 33% (2) 17% (1) 50% (3) Rectal 100% (3) 67% (2) 67% (2) 33% (1) 0 Anal 20% (1) 40% (2) 0 20% (1) 100% (5) Total 67% (12) 67% (12) 33% (6) 17% (3) 67% (12) Key: % (n) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis
Validation of first speech-specific questionnaire for English-speaking head and neck cancer (HNC) patients.
Authors: R. Kazi, R. C. Dwivedi, S. St. Rose, J. W. Roe, C. Nutting, P. H. Rhys-Evans, K. J. Harrington
Journal: Journal of Clinical Oncology (2010)

9081 Background: Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking HNC patients. The aim of this study is to validate the Speech Handicap Index (SHI) as the first speech-specific questionnaire in the English language. Methods: Sixty-three consecutive English-speaking patients in follow-up for oral or oropharyngeal cancers at The Royal Marsden Hospital, London, UK were recruited for this study. English version of Speech Handicap Index (SHI) is based on the widely used voice-specific scale the “Voice Handicap Index” (VHI). It consists of 30 well-constructed questions to evaluate the patient's speech and psycho-social functions. Patients were given both the questionnaires (SHI and UWQOL) in the outpatient for returning via post. A randomly selected subset of thirty-two patients was asked to complete both the questionnaires again after four weeks in order to assess test-retest reliability. Internal consistency and test-retest reliability were assessed using Cronbach's alpha and Spearman's correlation coefficient, respectively. Construct (by UWQOL V.04) and group validity were determined using the Mann-Whitney U-test. Results: The internal consistency reliability for Total SHI and SHI speech domain as calculated by Cronbach's alpha coefficient was 0.98 and 0.95, respectively. For SHI psycho-social domain alpha coefficient was 0.98. Test-retest reliability of Total SHI and SHI speech domain as calculated by Spearman's rank correlation coefficients were 0.92 and 0.88, respectively. For SHI psycho-social domain the coefficient was 0.89. The correlation coefficients between Total SHI score, the SHI speech domain, the SHI psycho-social domain and overall SHI speech assessment question, and speech domain of UWQOL were 0.72, 0.72, 0.71 and 0.68, respectively. The correlation coefficients between Total SHI score, the SHI speech domain, the SHI psycho-social domain and overall SHI speech assessment question, and social domain of the UWQOL were 0.44, 0.44, 0.43 and 0.35, respectively. Conclusions: The SHI is a precise, highly reliable and valid speech assessment tool for HNC patients. No significant financial relationships to disclose.
Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer.
Authors: Y Z Patt, A W Boddie, C Charnsangavej, J A Ajani, S Wallace, M Soski, L Claghorn, G M Mavligit
Journal: Journal of Clinical Oncology (1986)

Cisplatin (CDDP) was combined with floxuridine (FUDR) and delivered into the hepatic arteries of 29 patients as induction therapy for colorectal cancer metastatic to the liver. Mitomycin C and FUDR combination was substituted after progression or when response had peaked. Chemotherapy was delivered with an Infusaid pump (Infusaid Corp; Norwood, Mass; 14 patients), Medtronic programmable drug administration device (Medtronic, Inc, Minneapolis; two patients), or percutaneously placed catheters (13 patients). Complete disappearance of liver metastases was observed in four patients and 11 additional patients had a partial remission as determined by computed tomography (CT) scan and substantiated at times by angiography, for a total response rate of 52%. Response as determined by imaging techniques coincided with a concurrent decrease in carcinoembryonic antigen (CEA) and improvement in performance status. The severity of tumor burden was correlated with the response to therapy and survival. Among those patients who responded to arterial chemotherapy, differences in disease severity did not significantly influence survival. Median survival among responders with greater than 25% liver replacement by tumor was 14 months (P = .28), compared with 28 months for those patients with less than 25% liver replacement. In contrast, differences in tumor burden significantly affected survival among patients who failed to respond to chemotherapy; median survival among nonresponding patients with greater than 25% liver replacement was 4 months, compared with 8 months for those who had less than 25% liver replacement (P = .01). The presence of minimal extrahepatic disease at the time of initiation of intraarterial treatment did not seem to have a significant detrimental effect on survival. The study suggests that hepatic tumor response to arterial administration of CDDP and FUDR and mitomycin C and FUDR is clinically significant because it overrides the effect of tumor burden on survival among patients who have colorectal cancer with liver metastases and may offer effective palliation.
Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status
Authors: Christopher B. Benton, Lisa Gu, Hagop M. Kantarjian, Peng Qiu, Farhad Ravandi, Guillermo Garcia-Manero, Sherry Pierce, Mark Brandt, Marina Konopleva, Jorge E. Cortes, Michael Andreeff, Alfonso Quintas-Cardama
Journal: Blood (2013)
Phase I study of oral fluoropyrimidine anticancer agent (S-1) with concurrent external-beam radiotherapy for unresectable pancreatic cancer
Authors: H. Shinchi, S. Takao, K. Maemura, H. Noma, T. Aikou
Journal: Journal of Clinical Oncology (2006)

4109 Background: S-1 is an oral fluorouracil anticancer agent that was recently reported to demonstrate a response rate of 21% in 19 patients with advanced pancreatic cancer. Concurrent external-beam radiotherapy (EBRT) and 5-FU has been generally accepted as the standard treatment for locally advanced pancreatic cancer. However, there are no published data regarding the efficacy of combination therapy of S-1 and radiation in patients with pancreatic cancer. Our purpose of this study was to evaluate the safety of S-1 combined with EBRT and determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of S-1 in patients with locally advanced and unresectable pancreatic cancer. Methods: Eligible patients had UICC stage III or IV pancreatic cancer (either advanced unresectable or metastatic), adequate organ function, and no anticancer therapy in the preceding 4 weeks. S-1 was given orally at a dose of 60 mg/m 2 /day or 80 mg/m 2 /day in two divided doses after breakfast and supper. External-beam radiotherapy was delivered using a conformal technique in fraction of 1.25 Gy X 2/day, 5 days per week, totaling 50 Gy/40 fraction for 4weeks. S-1 at a dose of 60 mg/m 2 /day was given on days 1–7 and 15–21 in level 1, on days 1–14 in level 2, on days 1–21 in level 3a, respectively. S-1 at a dose of 80 mg/m 2 /day was given on days 1–21 in level 3b and on days 1–28 in level 4. DLT was defined as NCI-CTC grade 3/4 toxicity. Results: 18 patients were entered in this phase I trial: level 1 (4 patients), level 2 (5 patients), level 3a (3 patients), level 3b (3 patients), level 4 (3 patients). There were 1 of 5 patients with DLT in level 2: grade 3 vomiting. There were no DLT in levels 1, 3a, and 3b, respectively. Two of 3 patients in level 4 showed DLT: one patient developed grade 3 neutropenia and another patient developed grade 3 diarrhea. Clinical effects by CT scan included one PR, 15 SD and 2 PD. Reduced CA19–9 level less than a half of that at starting time was observed in 6 of 18 patients. Conclusions: S-1 at a dose of 80 mg/m 2 /day given on days 1–21 is safe and may be recommended for phase II study in patients with locally advanced and unresectable pancreatic cancer. This regimen appears to be a promising and well-tolerated approach with consideration of application to outpatients. No significant financial relationships to disclose.
Stimulation of Proliferation in Mixed Cultures of Mouse Tumor Cells and Nonimmune Peritoneal Cells. II. Stimulation of Tumor Cells by Macrophages and of Lymphocytes by a Tumor Cell Product&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: M Nelson, D S Nelson
Journal: JNCI Journal of the National Cancer Institute (1985)

Stimulation of [methyl-3H]thymidine incorporation in mixed cultures of mouse peritoneal cells (PC) and tumor cells required a large adherent PC. Flow cytometric analysis, as well as autoradiography, showed that the stimulation involved increased proliferation of tumor cells. The stimulation required contact between tumor and PC; it was partly inhibited by Trasylol (aprotinin) and potentiated by dexamethasone. In addition, there was minor stimulation of PC by a soluble product of tumor cells; this stimulation was not affected by Trasylol or dexamethasone. It is suggested that macrophages can stimulate tumor cell proliferation and that such stimulation may be an important factor in host-tumor relationships.
Abstract 11892: Safety and Pharmacokinetics of a Novel Formulation of Human Apolipoprotein A-I (CSL112) in Healthy Subjects: Results of a Placebo-Controlled, Randomized Multiple Ascending Dose Study
Authors: Rachael Easton, Louise Tremper, Charles Shear
Journal: Circulation (2012)

CSL112 is a novel formulation of apolipoprotein (apo) A-I, the active component of HDL, purified from human plasma and reconstituted to form HDL particles suitable for IV infusion. CSL112 resembles...
MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
Authors: G Cimino, G P Biti, A P Anselmo, R Maurizi Enrici, G P Bellesi, A Bosi, L Cionini, V Mungai, G Papa, P Ponticelli
Journal: Journal of Clinical Oncology (1989)

In order to assess whether mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy (CT), which is less expensive and more easily available than radiotherapy (RT), is at least as effective as RT in terms of cure rate and has less iatrogenic damage, 89 consecutive patients with Hodgkin's disease (HD) (pathological stage I-IIA) were randomly allocated to receive mantle plus lumbar bar RT (36-45 Gy) or CT (six courses of MOPP). Forty-five patients were entered in the RT group and 44 in the CT group. The median follow-up was 60 months. Complete remission (CR) was obtained in all patients in the RT group and in 40 of 44 patients in the CT group. Overall survival (OS) and disease-free survival (DFS) were, respectively, 87.2% and 72.7% in the CT group and 93.5% and 74% in the RT group. Survival probability of relapsing patients was 76% for the patients in the RT group and 45% in the CT group. Treatment-related complications were more severe in the CT group as compared with the RT group.
Accelerated partial breast irradiation using intensity modulated radiotherapy: Dose-volume histogram comparison with standard breast irradiatio
Authors: M. A. Lacombe, W. Al-Najjar, J. McMahon, V. Raghavan, W. D. Bloomer
Journal: Journal of Clinical Oncology (2004)

701 Background: Whole breast fractionated radiotherapy is the standard of care for breast conservation therapy. Studies have failed to identify a subset of patients who do not benefit from radiotherapy. The majority of recurrences occur near the site of the primary. Intensity modulated radiotherapy (IMRT) allows the treatment of smaller volumes with precision and is non-invasive. Limited volumes allow for treatment on an accelerated schedule. The doses delivered to surrounding organs can possibly be reduced using IMRT. Patient intratreatment motion, expected daily setup variation, and difficulty identifying target volume potentially limit the utility of this precise treatment. Methods: 70 node-negative postmenopausal patients with early-stage breast cancer, treated with lumpectomy (with negative margins) were selected to receive accelerated partial breast irradiation using IMRT. CT simulation was used to identify the post lumpectomy seroma as a target volume. Standard positioning devices were used for patient set-up. Treatment plans for both whole breast and partial breast irradiation were performed and compared using dose-volume histograms. 43.2 Gy was delivered in 16 daily fractions. Positioning was verified with twice weekly orthogonal port films. Acute toxicity during treatment was monitored and recorded. Results: The target volume was easily identified on CT simulation in all but three patients. Dose-volume histograms revealed a dramatic decrease in the amount of lung receiving even minimal doses of radiation. The dose to the heart and contralateral breast using IMRT was negligible. Daily variation in patient set-up was very minimal. The overwhelming majority of port films were approved as correct (over 85%). Acute toxicty was minimal. Conclusions: Accelerated partial breast irradiation is feasible for selected patients. The target volume is easily identified. IMRT dramatically reduces doses to normal tissue. Daily set-up and treatment is very reproducable. Acute toxicity is negligible. Treatment can be delivered in less than half the time of standard fractionated breast treatment. No significant financial relationships to disclose.
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
Authors: Gareth Walters, Hon Sum Liu, Monika Gemza, Farrukh Rauf
Journal: European Respiratory Journal (2011)

BTS guidelines on management of community acquired pneumonia suggest that failure of c-reactive protein (CRP) to resolve by ≥50% during admission predicts complication1. We aimed to see whether a high admission CRP or non-resolving CRP predicted adverse outcome in bacterial pneumonia. We undertook a retrospective cohort study of adults (n=197) admitted to our hospital with bacterial pneumonia 2005-10. Age, length of stay (LOS), CRP on admission and subsequent CRPs were recorded from electronic patient data. We measured incidence of abscess, parapneumonic effusion, empyema, ITU admission and all-cause mortality within 30 days of admission, as adverse events. Incidence of adverse events within 30 days: abscess (0%); effusion (9.6%); empyema (5.2%); ITU admission (7.6%); death (12.2%). CRP≥300mg/L on admission increased probability of ITU admission (p=0.006;OR=6.5 (1.93-21.86)) but not effusion, empyema or all-cause mortality. However, CRP≥100mg/L on admission was not associated with increased probability of adverse event; although median LOS was 8 days (IQR 4-20), compared to 6 (IQR 2-12.5) for CRP  1BTS Community Acquired Pneumonia in Adults Guideline Group. Thorax 2009;64:s3(1-55).
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease
Authors: V Diehl, M Loeffler, M Pfreundschuh, U Ruehl, D Hasenclever, H Nisters-Backes, M Sieber, K Smith, H Tesch, W Geilen
Journal: Annals of Oncology (1995)
A Policy Prescription for Hospice Care
Authors: Oreofe O. Odejide
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Exterior Palace
Authors: Jack Coulehan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 182: Mimetic peptide overcomes dysregulated L-Type Calcium Channel density and recovers myocardial function
Authors: Francesca Rusconi, Michele Miragoli, Elisa Di Pasquale, Marcella Rocchetti, Paola Ceriotti, Pierluigi Carullo, Silvia Caprari, Giacomo Viggiani, Magali Cazade, Jean Chemin, Marie-Louise Bang, Fabio Polticelli, Antonio Zaza, Gianluigi Condorelli, Daniele Catalucci
Journal: Circulation Research (2014)

Voltage dependent L-Type calcium-channels (LTCCs) are located on the cardiomyocyte membrane and regulate cardiac contraction and rhythmicity. In human pathologies, such as heart failure (HF), decreased inward calcium current (I Ca ) is frequently observed. Here, we generated a mimetic peptide (MP) that targets LTCCs and restores impaired intracellular calcium homeostasis through a novel mechanism. Effective delivery of MP, fused with a cell penetrating peptide, was found to correct Ca2+ alterations in a mouse model of HF, in human cardiomyocytes derived from induced pluripotent stem-cells. These data provide a proof-of-concept supporting a therapeutic role for MP to treat human diseases related to LTCC abnormalities. Category: heart failure biology
Abstract P313: De-Conditioning Adversely Affects Subclinical Atherosclerosis in a Unique Cohort of Spinal Cord Injury
Authors: Yaga Szlachcic, Rodney H Adkins, Jamie C Reiter, Yanjie Li, Howard N Hodis
Journal: Circulation (2012)

Introduction: Physical activity is presumed to improve cardiovascular disease (CVD), of which carotid artery intima-media thickness (CIMT) is a common indicator. Individuals with spinal cord injury (SCI) have limited mobility and therefore an expected increased risk for CVD. The purpose of this study was to determine which CVD risk factors predict CIMT among women with SCI, with the ultimate goal of targeting therapy to improve CVD in this population. Methods: One hundred twenty-two women with SCI who attended an outpatient SCI clinic and met inclusion and exclusion criteria participated in this study. SCI was categorized into 1 of 4 categories: complete tetraplegia, incomplete tetraplegia, complete paraplegia, and incomplete paraplegia. Maximum heart rate and VO2 max were obtained using bicycle ergometry with ventilatory gas exchange and continuous electrocardiogram. Hierarchical regression was used to predict CIMT, with the first block including demographic variables (age, race, smoking status) and the second block including physiologic variables (total cholesterol, heart rate, VO2 max, BMI, fasting serum glucose, hemoglobin A1c, and blood pressure). Results: Similar findings were observed for left and right CIMT, therefore only results from right CIMT are reported. The overall model was significant, F(16,46)=8.53, p=.000. Adjusted R square was .54 for the first block of variables and increased significantly (p=.006) to .66 when the second block of variables was added. Significant predictors at alpha=.05 included age (beta=.51, t=4.79, p=.000) and max/peak heart rate (beta=−.336, t=−2.39, p=.02). At alpha=.10, A1c was significant (beta=.187, t=1.99, p=.053). Conclusions: Although low aerobic conditioning is a purported CVD risk factor, quantitative measurements of such lack a demonstrable relationship with subclinical atherosclerosis (CIMT), perhaps because of its reduced importance relative to other CVD risk factors in a mobile population. We found expected relationships with CIMT in our SCI population (i.e., age), however we also found a quantitative measure of aerobic conditioning (max/peak heart rate) to be associated with CIMT. Our data indicate that SCI individuals may bear a greater CVD burden from cardiac de-conditioning than the general population and that investigation of a cohort with mobility limitation may provide a unique opportunity to study the impact of physical conditioning on CVD risk.